Celecoxib Has a Positive Effect on the Overall Metabolism of Hyaluronan and Proteoglycans in Human Osteoarthritic Cartilage

Journal of Rheumatology

Volumn 30, Issue 11, 2003, Pages 2444-2451

  El Hajjaji, Hafida ^b   Marcelis, Annette ^b   Devogelaer, Jean Pierre ^b   Manicourt, Daniel Henri ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b NONE

Author keywords

Cartilage; Celecoxib; Diclofenac; Hyaluronan; Proteoglycans

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HYALURONIC ACID; PAPAIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEOGLYCAN;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CARTILAGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LONG TERM CARE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; TISSUE CULTURE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARTILAGE, ARTICULAR; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; OSTEOARTHRITIS; PROTEOGLYCANS; PYRAZOLES; SULFONAMIDES;

EID: 0242609028     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Hardingham T. Proteoglycans and glycosaminoglycans. In: Seibel MJ, Robins SP, Bilezikian JP, editors. Dynamics of bone and cartilage metabolism. San Diego: Academic Press; 1999:71-81.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
3. Smith WL, Garavito RM, Dewitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-60.
4. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-8.
5. Gilroy, DW, Tomlinson A, Willoughby DA. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur J Pharmacol 1998;355:211-7.
6. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities in the altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995;378:406-9.
7. Gretzer B, Ehrlich K, Maricic N, Lambrecht N, Respondek M, Peskar BM. Selective cyclo-oxygenase-2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Br J Pharmacol 1998;123:927-35.
8. Schmassmann A, Peskar BM, Stettler C, Netzer P, Stroff FT, Flogerzi B, Halter F. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 1998;123:795-804.
9. Howell DS, Pita JC, Muller FJ, Manicourt DH, Altman RD. Treatment of OA with tiaprofenic acid: biochemical and histological protection against cartilage breakdown in the Pond-Nuki canine model. J Rheumatol 1991;18 Suppl 27:138-42.
10. Brandt KD. Should osteoarthritis be treated with nonsteroidal anti-inflammatory drugs? Rheum Dis Clin North Am 1993;19:697-712.
11. Ratcliffe A, Azzo W, Saed-Nejad F, Lane N, Rosenwasser MP. Mow VC. In vivo effects of naproxen on composition, proteoglycan metabolism, and matrix metalloproteinase activities in canine articular cartilage. J Orthop Surg 1993;11:163-71.
12. Manicourt D H, Druetz-Van Egeren A, Haazen L, Nagant de Deuxchaisnes C. Effects of tenoxicam and aspirin on the metabolism of proteoglycans and hyaluronan in normal and osteoarthritic human articular cartilage. Br J Pharmacol 1994;113:1113-20.
13. Dingle JT. Non-steroidal anti-inflammatory drug administration in the treatment of osteoarthritis. In: Reginster J-Y, Pelletier J-P, Martel-Pelletier J, Henrotin Y. editors. Osteoarthritis. Clinical and experimental aspects. Berlin: Springer-Verlag; 1999:370-87.
14. Blot L, Marcelis A, Devogelaer JP, Manicourt DH. Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human articular cartilage. Br J Pharmacol 2000;131:1413-21.
15. Hardy MM, Seibert K, Manning PT, et al. Cyclooxygenase 2-dependent prostaglandin E2 modulates cartilage proteoglycan degradation in human osteoarthritic explants. Arthritis Rheum 2002;46:1789-803.
16. Mastbergen SC, Lafeber FP, Bijlsma JW. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology 2002;41:801-8.
17. Manicourt DH, Pita JC. Progressive depletion of hyaluronic acid in early experimental osteoarthritis in dogs. Arthritis Rheum 1988;31:538-44.
18. Sweet MB, Thonar EJ, Immelman AR, Solomon L. Biochemical changes in progressive osteoarthrosis. Ann Rheum Dis 1977;36:387-98.
19. Thonar EJ, Sweet MB, Immelman AR, Lyons G. Hyaluronate in articular cartilage: age-related changes. Calcif Tissue Res 1978;26:19-21.
20. Rizkalla G, Reiner A, Bogoch E, Poole AR. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence of molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 1992;90:2268-77.
21. Holmes MW, Bayliss MT, Muir H. Hyaluronic acid in human articular cartilage. Age-related changes in content and size. Biochem J 1988;250:435-41.
22. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg 1971;53A:523-37.
23. Muir H. Current and future trends in articular cartilage research and osteoarthritis. In: Kuettner K, Schleyerbach DVM, Hascall VC, editors. Articular cartilage biochemistry. New York: Raven Press; 1986:423-40.
24. Woessner JF Jr. The determination of hydroxyproline in tissue and protein samples containing a small portion of this amino acid. Arch Biochem Biophys 1961;93:440-7.
25. Bitter T, Muir H. A modified uronic acid carbazole reaction. Anal Biochem 1962;4:330-4.
26. Li XQ, Thonar EJ-MA, Knudson W. Accumulation of hyaluronate in human lung carcinoma as measured by a new hyaluronate ELISA. Connect Tissue Res 1989;19:243-53.
27. Rashad S, Revell P, Hemingway A, Low F, Rainsford K, Walker F. Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis. Lancet 1989;8662:519-22.
28. Huskisson EC, Berry H, Gishen P, Jubb RW, Whitehead J. Effects of anti-inflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group. Longitudinal investigation of nonsteroidal anti-inflammatory drugs in knee osteoarthritis. J Rheumatol 1995;22:1941-6.
29. Netter P, Bannwarth B, Royer-Morrot MJ. Recent findings on the pharmacokinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 1989;17:149-62.
30. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000;38:225-42.
31. Hardingham TE, Muir H, Kwan MK, Lai WM, Mow VC. Viscoelastic properties of proteoglycan solutions with varying proportions present as aggregates. J Orthop Res 1987;5:36-46.
32. Pita JC, Muller FJ, Manicourt DH, Buckwalter JA, Ratcliffe A. Early matrix changes in experimental osteoarthritis and joint disuse atrophy. In: Kuettner K, Schleyerbach DVM, Peyron JG, Hascall VC, editors. Articular cartilage and osteoarthritis. New York: Raven Press; 1992:455-69.
33. Hiscock DR, Caterson B, Flannery CR. Expression of hyaluronan synthases in articular cartilage. Osteoarthritis Cartilage 2000;8:120-6.
34. Ng CK, Handley CJ, Preston BN, Robinson HC, Bolis S, Parker G. Effect of exogenous hyaluronan and hyaluronan oligosaccharides on hyaluronan and aggrecan synthesis and catabolism in adult articular cartilage explants. Arch Biochem Biophys 1995;316:596-606.
35. Minta JO, Williams MD. Some nonsteroidal antiinflammatory drugs inhibit the generation of superoxide anions by activated polymorphs by blocking ligand-receptor interactions. 1985;12:751-7.
36. Palmoski MJ, Brandt KD. Relationship between matrix proteoglycan content and the effects of salicylate and indomethacin on articular cartilage. Arthritis Rheum 1983;26:528-31.
37. Hugenberg ST, Brandt KD, Cole CA. Effects of salicylate, aspirin and ibuprofen on enzymes required by the chondrocyte for synthesis of chondroitin sulfate. J Rheumatol 1993;20:2128-33.
38. 2 synthesis in intact canine knee cartilage ex vivo. Arthritis Rheum 1984;27:398-403.
39. Heinegard D, Hascall VC. Aggregation of cartilage proteoglycans. III. Characteristics of the proteins isolated from trypsin digests of aggregates. J Biol Chem 1974;249:4250-6.
40. Lark MW, Bayne EK, Flanagan J, et al. Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997;100:93-106.
41. Tortorella MD, Burn TC, Pratta MA, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of protein. Science 1999;284:1664-6.
42. Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acid. Biochemistry 1992;31:7152-4.
43. Akimoto H, Yamazaki R, Hashimoto S, Sato T, Ito A. 4-Hydroxy aceclofenac suppresses the interleukin-1 induced production of promatrix metalloproteinases and release of sulfated-glycosaminoglycans from rabbit articular chondrocytes. Eur. J Pharmacol 2000;401:429-36.
44. Barracchini A, Franceschini N, Amicosante G, et al. Can non-steroidal and-inflammatory drugs act as metalloproteinase modulators? An in-vitro study of inhibition of collagenase activity. J Pharm Pharmacol 1998;50:1417-23.
45. Takahashi Y, Kawahara F, Noguchi M, et al. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or 2. FEBS Lett 1999;460:145-8.